[ORGANIZATION]
CagriSema
Featured in 10 tracked stories · first seen
Situations
Novo Nordisk raises 2026 outlook on Wegovy demand
117 clusters · 557 sources · last updated
Latest: Omada Health and Novo Nordisk present new obesity treatment data
Novo Nordisk is navigating market volatility and patent risks, specifically the potential for generic competition as U.S. patents for its primary active ingredients expire in 2032. While the company faces intense competi
GLP-1 receptor agonist research and safety scrutiny
13 clusters · 72 sources · last updated
Latest: GLP-1 medications face scrutiny over vision loss risks and clinical developments
Research into GLP-1 receptor agonists (GLP-1 RAs) has expanded to investigate health benefits beyond glycemic control and weight loss, specifically regarding bone health, pain, and inflammation. Studies involving adults
Novo Nordisk CagriSema clinical trial results
3 clusters · 13 sources · last updated
Latest: Novo Nordisk reports weight loss data for Wegovy and CagriSema
Novo Nordisk has released findings from Phase 3 clinical trials regarding its experimental medication, CagriSema, which combines cagrilintide and semaglutide to treat diabetes and obesity. Initial results from the Phase